Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme

  1. Ruilope, L.M.
  2. Redón, J.
  3. Schmieder, R.
Aldizkaria:
Vascular Health and Risk Management

ISSN: 1176-6344

Argitalpen urtea: 2007

Alea: 3

Zenbakia: 1

Orrialdeak: 1-9

Mota: Berrikuspena

GOOGLE SCHOLAR
Datuen iturria: Scopus